| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Kroll Mark W serves as a Director at HAE and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 1 buy and 35 sells.
Historically, Kroll Mark W's trades have earned a below-average insider score of 36/100 across 6 rated trades. Over a 12-month horizon, 20.0% of those trades were profitable, with an average 12-month return of -27.2%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 10, 2025 | HAE Haemonetics Corp | Director | Buy | 1,400 | $70.56 | $98,784.00 | +6.0% | -18.1% | - | |
| Mar 7, 2023 | Director | Sell | 3,549 | $220.73 | $783,361.07 | -25.9% | -13.7% | +41.7% | ||
| Aug 15, 2022 | HAE Haemonetics Corp | Director | Sell | 8,016 | $73.71 | $590,859.36 | -33.1% | +2.3% | +22.3% | |
| Jun 8, 2022 | Director | Sell | 3,159 | $102.82 | $324,795.74 | -18.7% | +14.4% | +89.3% | ||
| May 26, 2021 | HAE Haemonetics Corp | Director | Sale+OE | 11,813 | $55.10 | $650,896.30 | -39.0% | +10.1% | +12.3% | |
| May 12, 2021 | Director | Sell | 4,204 | $124.94 | $525,260.37 | -23.9% | +48.1% | -29.9% | ||
| Nov 16, 2020 | Director | Sell | 2,993 | $120.44 | $360,476.92 | -13.9% | - | - | ||
| Apr 9, 2020 | HAE Haemonetics Corp | Director | Sale+OE | 10,902 | $102.00 | $1,112,004.00 | -37.2% | - | - | |
| Nov 13, 2019 | Director | Sell | 4,168 | $64.30 | $267,987.40 | -17.6% | - | - | ||
| Nov 7, 2018 | HAE Haemonetics Corp | Director | Sale+OE | 10,707 | $114.00 | $1,220,598.00 | -30.2% | - | - |